Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Profound MedicalPROF +1.16%69 Cash-to-Debt is 6.74 as of Mar. 2026, which is 23% above its 10-year median of 5.46. GuruFocus rates PROF with a GF Score™ of 69/100 and a GF Value™ of $14.47 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 848 Medical Devices & Instruments companies, Profound Medical ranks better than 69.58% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Profound Medical's cash to debt ratio for the quarter that ended in Mar. 2026 was 6.74.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Profound Medicalcould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Profound Medical's Cash-to-Debt or its related term are showing as below:
PROF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.35 Med: 5.46 Max: 50.06
Current: 6.74
During the past 12 years, Profound Medical's highest Cash to Debt Ratio was 50.06. The lowest was 1.35. And the median was 5.46.
PROF's Cash-to-Debt is ranked better than 69.58% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: 1.65
vs PROF: 6.74
Profound Medical (NAS:PROF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Profound Medical Cash-to-Debt Related Terms
Profound Medical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Profound Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Profound Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Profound Medical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a Cash-to-Debt of 6.74 as of Mar. 2026. This is 23% above median its historical median of 5.46. Over the past decade, Profound Medical's Cash-to-Debt has ranged from 1.35 to 50.06. According to the industry distribution chart, Profound Medical ranks #258 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 30.4%.
Is Profound Medical's Cash-to-Debt too high?
Profound Medical's current Cash-to-Debt of 6.74 is 23% above median its 10-year median of 5.46. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 50.06. The Medical Devices & Instruments industry median Cash-to-Debt is 1.65. Profound Medical's value of 6.74 is 308.5% above this industry median. Based on the distribution chart, Profound Medical ranks #258 out of 848 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Profound Medical has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #258 out of 848 companies for Cash-to-Debt. This puts Profound Medical in the upper half of its industry. The industry median Cash-to-Debt is 1.65. Profound Medical's value of 6.74 is 308.5% above this benchmark. Historically, Profound Medical's own Cash-to-Debt has ranged from 1.35 to 50.06 over the past decade. While the company's 10-year median is 5.46 vs. the industry median of 1.65, Profound Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.65, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Cash-to-Debt of 6.74 is 308.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Cash-to-Debt is 6.74, which is 23% above median its own 10-year median of 5.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.47, compared to a current price of $6.99 — trading 51.7% below its estimated fair value. The current Cash-to-Debt is 6.74, which is 23% above median its 10-year median of 5.46 and 308.5% above the Medical Devices & Instruments industry median of 1.65. Profound Medical's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Profound Medical (PROF), the current Cash-to-Debt is 6.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $6.99 is trading 51.7% below its estimated GF Value™ of $14.47.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Cash-to-Debt: 6.74 (23% above median its 10-year median of 5.46)
GF Value™: $14.47 vs. price of $6.99 (51.7% below fair value)
Industry Position: 308.5% above the Medical Devices & Instruments median (#258 of 848)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
69GF Score
Get the complete analysis for PROF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
